AI Summary & Key Takeaways
AI InsightNew biomarkers that would create a significant difference in these patients should be investigated.
📌 3 Key Takeaways
Abstract
Epilepsy is one of the neurological diseases that affects a significant number of individuals in the world. In addition to having important effects on the social lives of the patients, this disease is a significant cause of disability. Neurological mechanisms underlying the disease are still being investigated. The patients’ gender, age, hemogram parameters (white blood cells, hemoglobin, erythrocyte, neutrophil, lymphocyte, monocyte, eosinophil, platelet), arterial bold gas values, drugs used, presence of drug-resistant epilepsy, and the duration of the disease were analyzed. The patients were divided into two groups of similar ages and genders as drug-resistant epilepsy and drug-nonresistant epilepsy patients. This grouping was made according to ILAE classification by considering the patients’ anamnesis, clinical history, seizure frequency, and antiepileptic drugs currently used. 77 drug-resistant and 129 drug-nonresistant epilepsy patients, 206 in total, were included in the study. 64.9% of the drug-resistant epilepsy group were male, and the remaining 35.1% were female, while 65.9% of the drug-nonresistant epilepsy group were male and 34.1% were female. No significant difference was found between the groups in terms of systemic inflammatory indices. Disease duration of the patients in the drug-resistant epilepsy group was significantly higher than the disease duration of the patients in the drug-nonresistant epilepsy group. A negative and significant correlation was found between pH and pO2, pCO2, and lactate. In addition, a positive and significant correlation was determined between pO2 and lactate, and a negative and significant correlation was found between pO2 and pCO2. It was determined that there was no significant difference between drug-resistant epilepsy patients and drug-nonresistant epilepsy patients in terms of parameters used as a systemic inflammatory biomarker in epilepsy patients. New biomarkers that would create a significant difference in these patients should be investigated.